title: Prognostic factors for treatment of malignant lymphoma in dogs.
abstract: Pretreatment characteristics of 138 dogs with malignant lymphoma were analyzed to determine prognostic factors associated with outcome (ie, complete response rate, time to relapse after complete response, survival time). Dogs were all treated for 10 weeks, using a standard induction chemotherapy protocol, and were then given asparaginase weekly. Once the disease became progressive, second-line chemotherapy was instituted. Age, sex, weight, clinical stage, performance grade, immunophenotype, and malignancy grade assigned according to the National Cancer Institute's Working Formulation were not associated with complete response rate. However, malignancy grade assigned according to the Kiel classification was found to be associated with complete response rate; dogs with high-grade malignancies had a significantly higher complete response rate than did dogs with low-grade malignancies. By means of multivariate analysis, clinical stage and immunophenotype were found to be prognostic factors for time to relapse (among dogs that had had a complete response) and survival time. In addition, malignancy grade assigned according to the Kiel classification was found to be a prognostic factor for time to relapse; whereas, malignancy grade assigned according to the Working Formulation was determined to be a prognostic factor for survival time.
authors.affiliation: Department of Clinical Sciences of Companion Animals, Utrecht University, The Netherlands.
authors.forename: E
authors.initials: E
authors.lastname: Teske
authors.forename: P
authors.initials: P
authors.lastname: van Heerde
authors.forename: G R
authors.initials: GR
authors.lastname: Rutteman
authors.forename: I D
authors.initials: ID
authors.lastname: Kurzman
authors.forename: P F
authors.initials: PF
authors.lastname: Moore
authors.forename: E G
authors.initials: EG
authors.lastname: MacEwen
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D004800:Enzymes, Immobilized / Q000627:therapeutic use; D005260:Female; D016130:Immunophenotyping / Q000662:veterinary; D008223:Lymphoma / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004800:Enzymes, Immobilized; D011092:Polyethylene Glycols; C042705:pegaspargase; D001215:Asparaginase